177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Clinical trial NCT04167618 · TERMINATED
Trial details
- NCT number
- NCT04167618
- Sponsor
- Y-mAbs Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-30
- Primary completion
- 2022-08-11
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.